AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$EOLS

Evolus Inc (EOLS) (Q3 2026) Earnings Call Highlights: Fourth Consecutive Positive

Evolus Inc (EOLS) reported Q3 2026 adjusted EBITDA of $1.2M, up $4.2M YoY. Global toxin revenue grew 11%, with Jeuveau gaining market share. HA business (Evolysse/Estyme) grew 40% in the quarter. The company added 500+ new accounts, reaching 19,000+ customers. Evolus expects three product launches by 2030. The FDA issued an untitled letter regarding a Jeuveau Instagram post, which was removed. Q4 operating expenses are expected to rise due to seasonality and a $1.5M option payment.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 1:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 1:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Evolus Inc (EOLS) (Q3 2026) Earnings Call Highlights: Fourth Consecutive Positive — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$EOLSNeutralMed
01

Why it matters

Earnings beat and guidance reaffirmation suggest upside, but regulatory note adds downside risk.

02

Market read

Evolus' earnings and guidance provide fresh data for traders; regulatory note tempers enthusiasm.

03

What to watch

Potential expense increase in Q4 and competitive pressure from larger players acquiring skin‑care assets.

Relevance 7/10Novelty 8/10Timing: post‑earnings today

Background

Evolus Inc. (NASDAQ:EOLS) delivered its Q3 2026 earnings call, highlighting revenue growth, positive EBITDA, and reaffirmed full‑year guidance, while noting an FDA untitled letter on a Jeuveau Instagram post.

Company-level read

Ticker impact

$EOLSNeutralHigh confidence
Context

Q3 2026 earnings released with $78M revenue, positive adjusted EBITDA and full-year guidance reaffirmed.

Expected impact

modest upside as guidance beats expectations, tempered by FDA letter risk

Evidence & confidence

Positive earnings and guidance support price, while regulatory note may limit upside.

Market effects

Sector

Aesthetic injectables sector may see increased investor interest from Evolus' growth trajectory.

Regional

U.S. and international markets for aesthetic toxins could benefit from Evolus' double‑digit Jeuveau growth.

Global

Limited to the niche aesthetic market; broader market impact minimal.

Counterpoint

What could challenge this read

Regulatory scrutiny from the FDA letter could signal deeper compliance issues, risking a pullback.

Key entities

  • company
    Evolus Inc.

    Aesthetic injectables manufacturer reporting Q3 2026 results.

  • regulator
    FDA

    Issued an untitled letter regarding a Jeuveau Instagram post.

Read at source← All news

StoryEvolus reports Q3 2026 earnings with positive adjusted EBITDA and reaffirms 2028 revenue target

Also covered by

2 outlets

Related articles

$EOLSMed

What Evolus (EOLS) Said on Its Q3 Earnings Call

Evolus (EOLS) cut its full-year non-GAAP operating expense guidance to $210M-$213M and reaffirmed 2028 revenue targets of $450M-$500M with adjusted EBITDA margins of 13%-15%. The company expects FDA approval for Sculpt in Q4 2026 and a 2027 launch. Evolysse and Estyme gel lines are projected to contribute 10%-12% of full-year revenue. Evolus added over 500 purchasing accounts, bringing its total to over 19,000.

finance.yahoo.com
$EOLSMed

Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA…

Evolus, Inc. (EOLS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook • Global Net Revenue of $78.0 Million for the Third Quarter of 2026, an Incre

SEC EDGAR 8-K
$EOLSMed

Evolus (EOLS) Shares Fall After FDA Warning on Jeuveau Instagram

Evolus Inc (EOLS) shares fell after the FDA issued a warning over a misleading Instagram post about its product Jeuveau. The company must submit a corrective action plan within 15 days. Evolus's P/S ratio is 1.49, below its historical median, and it has a GF Score of 74/100. Insiders have sold $1.8 million in shares over the past year. Jeuveau accounts for over 90% of the company's revenue, which totaled $316.5 million over the trailing twelve months.

gurufocus.com